Research ExplorerPublicationsDNA methylation of sarcosine dehydrogenase (SARDH) loci as a...

DNA methylation of sarcosine dehydrogenase (SARDH) loci as a prognosticator for renal cell carcinoma

Standard

DNA methylation of sarcosine dehydrogenase (SARDH) loci as a prognosticator for renal cell carcinoma. / Mazdak, Mehrdad; Tezval, Hossein; Callauch, Janne Carmen; Dubrowinskaja, Natalia; Peters, Inga; Hennenlotter, Jörg; Stenzl, Arnulf; Kuczyk, Markus A; Serth, Jürgen.

In: Oncology reports, Vol. 42, No. 5, 11.2019, p. 2159-2168.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Mazdak, M, Tezval, H, Callauch, JC, Dubrowinskaja, N, Peters, I, Hennenlotter, J, Stenzl, A, Kuczyk, MA & Serth, J 2019, 'DNA methylation of sarcosine dehydrogenase (SARDH) loci as a prognosticator for renal cell carcinoma', Oncology reports, vol. 42, no. 5, pp. 2159-2168. https://doi.org/10.3892/or.2019.7305

APA

Mazdak, M., Tezval, H., Callauch, J. C., Dubrowinskaja, N., Peters, I., Hennenlotter, J., Stenzl, A., Kuczyk, M. A., & Serth, J. (2019). DNA methylation of sarcosine dehydrogenase (SARDH) loci as a prognosticator for renal cell carcinoma. Oncology reports, 42(5), 2159-2168. https://doi.org/10.3892/or.2019.7305

Vancouver

Mazdak M, Tezval H, Callauch JC, Dubrowinskaja N, Peters I, Hennenlotter J et al. DNA methylation of sarcosine dehydrogenase (SARDH) loci as a prognosticator for renal cell carcinoma. Oncology reports. 2019 Nov;42(5):2159-2168. https://doi.org/10.3892/or.2019.7305

Bibtex

@article{780921f070cc4f4cb351aea1e5b543db,
title = "DNA methylation of sarcosine dehydrogenase (SARDH) loci as a prognosticator for renal cell carcinoma",
abstract = "DNA methylation plays an important role in the genesis and progression of tumor diseases. To identify new DNA methylation markers possibly associated with the clinical characteristics of renal cell carcinoma (RCC), we investigated loci in the sarcosine dehydrogenase (SARDH) gene. SARDH is involved in the metabolism of the glycine‑derivative sarcosine and is closely linked through a functional control loop. Statistical evaluation of methylation data and clinical characteristics of patients showed that kidney tumors with clinically aggressive features such as a high tumor stage, positive lymph nodes, distant metastases or a previously advanced tumor status exhibited significantly lower methylation of a locus in the SARDH gene. Moreover, SARDH methylation was found to be a significant prognostic factor for recurrence‑free survival in RCC patients showing statistical independence from the clinical prognosticators, grade, stage and state of metastasis. In conclusion, the methylation status of the SARDH‑CGI was identified as an independent prognostic candidate marker for RCC.",
author = "Mehrdad Mazdak and Hossein Tezval and Callauch, {Janne Carmen} and Natalia Dubrowinskaja and Inga Peters and J{\"o}rg Hennenlotter and Arnulf Stenzl and Kuczyk, {Markus A} and J{\"u}rgen Serth",
year = "2019",
month = nov,
doi = "10.3892/or.2019.7305",
language = "English",
volume = "42",
pages = "2159--2168",
journal = "ONCOL REP",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "5",

}

RIS

TY - JOUR

T1 - DNA methylation of sarcosine dehydrogenase (SARDH) loci as a prognosticator for renal cell carcinoma

AU - Mazdak, Mehrdad

AU - Tezval, Hossein

AU - Callauch, Janne Carmen

AU - Dubrowinskaja, Natalia

AU - Peters, Inga

AU - Hennenlotter, Jörg

AU - Stenzl, Arnulf

AU - Kuczyk, Markus A

AU - Serth, Jürgen

PY - 2019/11

Y1 - 2019/11

N2 - DNA methylation plays an important role in the genesis and progression of tumor diseases. To identify new DNA methylation markers possibly associated with the clinical characteristics of renal cell carcinoma (RCC), we investigated loci in the sarcosine dehydrogenase (SARDH) gene. SARDH is involved in the metabolism of the glycine‑derivative sarcosine and is closely linked through a functional control loop. Statistical evaluation of methylation data and clinical characteristics of patients showed that kidney tumors with clinically aggressive features such as a high tumor stage, positive lymph nodes, distant metastases or a previously advanced tumor status exhibited significantly lower methylation of a locus in the SARDH gene. Moreover, SARDH methylation was found to be a significant prognostic factor for recurrence‑free survival in RCC patients showing statistical independence from the clinical prognosticators, grade, stage and state of metastasis. In conclusion, the methylation status of the SARDH‑CGI was identified as an independent prognostic candidate marker for RCC.

AB - DNA methylation plays an important role in the genesis and progression of tumor diseases. To identify new DNA methylation markers possibly associated with the clinical characteristics of renal cell carcinoma (RCC), we investigated loci in the sarcosine dehydrogenase (SARDH) gene. SARDH is involved in the metabolism of the glycine‑derivative sarcosine and is closely linked through a functional control loop. Statistical evaluation of methylation data and clinical characteristics of patients showed that kidney tumors with clinically aggressive features such as a high tumor stage, positive lymph nodes, distant metastases or a previously advanced tumor status exhibited significantly lower methylation of a locus in the SARDH gene. Moreover, SARDH methylation was found to be a significant prognostic factor for recurrence‑free survival in RCC patients showing statistical independence from the clinical prognosticators, grade, stage and state of metastasis. In conclusion, the methylation status of the SARDH‑CGI was identified as an independent prognostic candidate marker for RCC.

U2 - 10.3892/or.2019.7305

DO - 10.3892/or.2019.7305

M3 - SCORING: Journal article

C2 - 31545450

VL - 42

SP - 2159

EP - 2168

JO - ONCOL REP

JF - ONCOL REP

SN - 1021-335X

IS - 5

ER -